Ge Healthcare Technologies INC 8-K filings

GE HealthCare announced flat year-over-year revenue and updated its full-year guidance due to challenges in the China market, despite margin expansion and solid orders growth in the U.S.

GE HealthCare Technologies Inc. successfully held its annual meeting on May 21, 2024, electing ten directors, approving executive compensation, and ratifying the appointment of Deloitte & Touche LLP as its independent auditor.

GE HealthCare's first quarter 2024 results show flat organic revenue growth and improved margins, with the company reaffirming its full-year guidance.

Jan Makela, Chief Executive Officer of Imaging at GE HealthCare Technologies Inc., has resigned effective July 8, 2024, to take a CEO position at a private company.

GE HealthCare has announced the pricing of a secondary offering of 14 million shares of its common stock, with General Electric expected to exchange the shares for debt.

GE HealthCare has announced a secondary offering of 13 million shares of its common stock, with General Electric Company (GE) expected to exchange the shares for debt held by Morgan Stanley.

GE HealthCare reported a 5% year-over-year revenue growth for the fourth quarter of 2023 and 7% for the full year, marking a strong first year as a public company.

GE HealthCare reported a 5% year-over-year revenue growth for the fourth quarter of 2023 and 7% for the full year, marking a strong first year as a public company.

GE HealthCare announced robust fourth quarter and full year 2023 financial results, marking a successful first year as a publicly traded company, and provided a positive financial outlook for 2024.

GE HealthCare Technologies Inc. has announced that its Chief People Officer, Betty D. Larson, will be resigning from her position effective March 21, 2024.